

Freedom of Information Request: Our Reference CTMUHB_87_26

You asked:

1. How many patients have been treated with the following drugs in the past 4 months:

- **Atogepant (Aquipta) – any disease**
- **Erenumab (Aimovig) - any disease**
- **Eptinezumab (Vyepti) – any disease**
- **Fremanezumab (Ajovy) - any disease**
- **Galcanezumab (Emgality) - any disease**
- **Rimegepant (Vydura) – any disease**
- **Botulinum Toxin (i.e., Botox, Dysport, Xeomin) - migraine ONLY**

Please find below three tables populated with the data that Medicines Management are able to provide at this current time.

The data provided for Secondary Care relates to the latest 4 months available which is 1st November 25 to 31st January 26.

Unfortunately, we are unable to provide Botulinum Toxin data by patient numbers because not all the issues are made to an individual therefore, we have provided Botulinum Toxin information by number of issues.

The data provided for Primary Care relates the latest 4 months available which is 1st August 25 to 30th November 25. Unfortunately, we are unable to provide this data by number of patients due to the way the information is recorded in the electronic systems.

Secondary Care

Medicine	Number of Patients
Atogepant (Aquipta) – any disease	26
Erenumab (Aimovig) - any disease	15
Eptinezumab (Vyepti) – any disease	0
Fremanezumab (Ajovy) - any disease	47
Galcanezumab (Emgality) - any disease	29
Rimegepant (Vydura) – any disease	29

Secondary Care

Medicine	Number of Issues
Botulinum Toxin (i.e., Botox, Dysport, Xeomin) - For any indication	379

Primary Care

Medicine	Items - Base Period
Rimegepant 75mg Oral Lyophilisates Sugar Free	130

2. How many patients have you treated in the last 4 months for acute migraine with:

- **Rimegepant (Vydura)**

Data on issue by indication (acute migraine) is not centrally recorded. The detailed information you require would be recorded within an individual patient's health record as part of their ongoing care. To provide you with this information, would require a manual trawl and significantly exceed the 18 hours time and £450 cost limit set out within Section 12 of the Freedom of Information Act.

3. Does the trust actively initiate a treatment pause (usually at 12 months) of anti-CGRP (calcitonin gene-related peptide inhibitors) migraine treatment with the aim to re-start treatment if the patient continues to fit the criteria (Yes/No)?

A treatment pause is routinely and actively considered at 12 months, but the decision to actually discontinue is made on a case-by-case basis and not necessarily mandated, depending upon patient characteristics.